Outcomes in 300 patients with low-risk ET followed with careful observation or treated with antiplatelet therapy
| . | Observation (848 person-years) . | Antiplatelet therapy (802 person-years) . | P . | ||
|---|---|---|---|---|---|
| No. of events . | Incidence rate* (95% CI) . | No. of events . | Incidence rate* (95% CI) . | ||
| Thrombosis (arterial and venous) | 15 | 17.7 (10.7-29.3) | 17 | 21.2 (13.2-34.1) | .6 |
| Arterial thrombosis | 8 | 9.4 (4.7-18.9) | 13 | 16.2 (9.4-27.9) | .2 |
| Venous thrombosis | 7 | 8.2 (3.9-17.3) | 4 | 4.9 (1.9-13.3) | .4 |
| Bleeding | 5 | 6.0 (2.5-14.5) | 10 | 12.6 (6.8-23.4) | .09 |
| . | Observation (848 person-years) . | Antiplatelet therapy (802 person-years) . | P . | ||
|---|---|---|---|---|---|
| No. of events . | Incidence rate* (95% CI) . | No. of events . | Incidence rate* (95% CI) . | ||
| Thrombosis (arterial and venous) | 15 | 17.7 (10.7-29.3) | 17 | 21.2 (13.2-34.1) | .6 |
| Arterial thrombosis | 8 | 9.4 (4.7-18.9) | 13 | 16.2 (9.4-27.9) | .2 |
| Venous thrombosis | 7 | 8.2 (3.9-17.3) | 4 | 4.9 (1.9-13.3) | .4 |
| Bleeding | 5 | 6.0 (2.5-14.5) | 10 | 12.6 (6.8-23.4) | .09 |
ET indicates essential thrombocythemia.
Events per 1000 person-years.